June 25, 2020 / 1:29 AM / a month ago

BRIEF-Suda Says Unable To Progress Licensing Deal For Cancer Therapy From U.S. Institute

June 25 (Reuters) - Suda Pharmaceuticals Ltd:

* NOT ABLE TO PROGRESS LICENSING DEAL FOR CANCER THERAPY TECHNOLOGY FROM A U.S. RESEARCH INSTITUTE

* ACCOMPANYING CAPITAL RAISING WILL ALSO NOT PROCEED AT THIS TIME Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below